Helena Idborg

Helena Idborg

Laboratory Coordinator
Visiting address: CMM, L8:02, Karolinska Universitetssjukhuset Solna, 17176 Stockholm
Postal address: K2 Medicin, Solna, K2 Reuma Jakobsson P, 171 77 Stockholm
Part of:

About me

  • Helena Idborg received her Ph.D. in Analytical Chemistry 2007 at Stockholm University, with the thesis entitled “Analysis of metabolites in complex biological samples using LC/MS and multivariate data analysis - Metabolic fingerprinting and detection of biomarkers”. She began her postdoc position at the Division of Rheumatology, Karolinska Institutet (KI), Sweden, in 2009, in the field of biomarker discovery and translational medicine within inflammatory and autoimmune diseases. Her research focus is on mass spectrometry based metabolomics, e.g., targeted lipidomics and prostaglandin profiling. Analysis of multiple omics data and correlation to clinical data is applied to study and identify pathological pathways, novel biomarkers and possible drug targets in rheumatic diseases, e.g. SLE, RA and SSc.

Articles

  • Article: ANNALS OF THE RHEUMATIC DISEASES. 2025;84(9):1549-1560
    Alabbasi S; Tacconelli S; de Vries M; Gunnarsson I; Oke V; Kvarnstrom M; De Michele A; Di Gregorio P; Patrignani P; Idborg H; Jakobsson P-J
  • Article: ANNALS OF THE RHEUMATIC DISEASES. 2025;84(7):1164-1179
    Lindblom J; Lagutkin D; Sherina N; Idborg H; Beretta L; Borghi MO; Peyper JM; Barturen G; Jakobsson P-J; Alarcon-Riquelme ME; Nikolopoulos D; Parodis I
  • Article: ANNALS OF THE RHEUMATIC DISEASES. 2025;84(7):1180-1194
    Parodis I; Lagutkin D; Lindblom J; Idborg H; Beretta L; Borghi MO; Peyper JM; Barturen G; Jakobsson P-J; Alarcon-Riquelme ME; Sherina N; Nikolopoulos D
  • Journal article: ANNALS OF THE RHEUMATIC DISEASES. 2025;83:248-249
    Alabbasi S; Tacconelli S; De Vries M; Gunnarsson I; De Michele A; DI Gregorio P; Patrignani P; Idborg H; Jakobsson PJ
  • Journal article: ANNALS OF THE RHEUMATIC DISEASES. 2025;84:948-949
    Cruciani C; Gatto M; Nikopoulos D; Lindblom J; Lagutkin D; Beretta L; Iagnocco A; Franco C; Fedrigo M; Idborg H; Peyper J; Barturen G; Doria A; Sherina N; Tamirou F; Alarcon-Riquelme M; Houssiau F; Parodis I
  • Journal article: ANNALS OF THE RHEUMATIC DISEASES. 2025;84:2169-2171
    Gonzalez-Sanchez AC; Idborg H; Jonsen A; Antovic A; Bengtsson A; Zickert A; Reid S; Chemin K; Ronnblom L; Gunnarsson I; Nordmark G; Svenungsson E; Leonard D; Diaz-Gallo LM
  • Article: BMC RHEUMATOLOGY. 2025;9(1):56
    Hambardzumyan K; Hamsten C; Lourido L; Saevarsdottir S; Nilsson P; van Vollenhoven RF; Jakobsson P-J; Idborg H
  • Journal article: JOURNAL OF RHEUMATOLOGY. 2025;52(Suppl 1):45
    Lindblom J; Lagutkin D; Sherina N; Idborg H; Beretta L; Borghi MO; Consortium PC; Peyper JM; Barturen G; Jakobsson P-J; Alarcón-Riquelme M; Nikolopoulos D; Parodis I
  • Journal article: JOURNAL OF RHEUMATOLOGY. 2025;52(Suppl 1):219-220
    Parodis I; Lagutkin D; Lindblom J; Idborg H; Beretta L; Borghi MO; Consortium PC; Peyper JM; Barturen G; Jakobsson P-J; Alarcón-Riquelme M; Sherina N; Nikolopoulos D
  • Journal article: JOURNAL OF RHEUMATOLOGY. 2025;52(Suppl 1):140-141
    Gonzalez-Sanchez AC; Idborg H; Jönsen A; Antovic A; Bengtsson A; Zickert A; Reid S; Chemin K; Rönnblom L; Gunnarsson I; Nordmark G; Svenungsson E; Leonard D; Diaz-Gallo L-M
  • Journal article: SCIENCE SIGNALING. 2025;18(887):eadw1245
    Schebb NH; Kampschulte N; Hagn G; Plitzko K; Meckelmann SW; Ghosh S; Joshi R; Kuligowski J; Vuckovic D; Botana MT; Sanchez-Illana A; Zandkarimi F; Das A; Yang J; Schmidt L; Checa A; Roche HM; Armando AM; Edin ML; Lih FB; Aristizabal-Henao JJ; Miyamoto S; Giuffrida F; Moussaieff A; Domingues R; Rothe M; Hinz C; Das US; Rund KM; Taha AY; Hofstetter RK; Werner M; Werz O; Kahnt AS; Bertrand-Michel J; Le Faouder P; Gurke R; Thomas D; Torta F; Milic I; Dias IHK; Spickett CM; Biagini D; Lomonaco T; Idborg H; Liu J-Y; Fedorova M; Ford DA; Barden A; Mori TA; Kennedy PD; Maxey K; Ivanisevic J; Gallart-Ayala H; Gladine C; Wenk M; Galano J-M; Durand T; Stark KD; Barbas C; Garscha U; Gelhaus SL; Ceglarek U; Flamand N; Griffin JL; Ahrends R; Arita M; Zeldin DC; Schopfer FJ; Quehenberger O; Julian R; Nicolaou A; Blair IA; Murphy MP; Hammock BD; Freeman B; Liebisch G; Serhan CN; Koefeler HC; Jakobsson P-J; Steinhilber D; Gelb MH; Holcapek M; Andrew R; Giera M; Fitzgerald GA; Murphy RC; Newman JW; Dennis EA; Ekroos K; Milne GL; Gijon MA; Vesper HW; Wheelock CE; O'Donnell VB
  • Article: JOURNAL OF AUTOIMMUNITY. 2024;149:103332
    Notarnicola A; Hellstrom C; Horuluoglu B; Pin E; Preger C; Bonomi F; De Paepe B; De Bleecker JL; van der Kooi AJ; De Visser M; Sacconi S; Machado P; Badrising UA; Rietveld A; Pruijn G; Rothwell S; Lilleker JB; Chinoy H; Benveniste O; Svenungsson E; Idborg H; Jakobsson P-J; Nilsson P; Lundberg IE
  • Article: ANALYTICAL AND BIOANALYTICAL CHEMISTRY. 2024;416(25):5485-5496
    Zohrer B; Gomez C; Jaumot J; Idborg H; Torekov SS; Wheelock AM; Wheelock CE; Checa A
  • Article: FRONTIERS IN IMMUNOLOGY. 2024;15:1372927
    Almeida L; van Roey R; Patente TA; Otto F; Veldhuizen T; Ghorasaini M; van Diepen A; Schramm G; Liu J; Idborg H; Korotkova M; Jakobsson P-J; Giera M; Hokke CH; Everts B
  • Article: ARTHRITIS RESEARCH & THERAPY. 2024;26(1):61
    Liu J; Idborg H; Korotkova M; Lend K; van Vollenhoven R; Lampa J; Rudin A; Nordstrom D; Gudbjornsson B; Grondal G; Uhlig T; Horslev-Petersen K; Merete HL; Ostergaard M; Nurmohamed M; Jakobsson P-J
  • Journal article: FRONTIERS IN IMMUNOLOGY. 2024;15:1372927
    Almeida L; van Roey R; Patente TA; Otto F; Veldhuizen T; Ghorasaini M; van Diepen A; Schramm G; Liu J; Idborg H; Korotkova M; Jakobsson P-J; Giera M; Hokke CH; Everts B
  • Article: PROSTAGLANDINS & OTHER LIPID MEDIATORS. 2023;167:106738
    Liu J; Peng B; Steinmetz-Spah J; Idborg H; Korotkova M; Jakobsson P-J
  • Article: BRITISH JOURNAL OF PHARMACOLOGY. 2023;180(15):1981-1998
    Zhang Y; Steinmetz-Spah J; Idborg H; Zhu L; Li H; Rao H; Chen Z; Guo Z; Hu L; Xu C; Chen H; Korotkova M; Jakobsson P-J; Wang M
  • Article: LUPUS. 2023;32(2):252-262
    Faustini F; Idborg H; Fuzzi E; Larsson A; Lie W-R; Poetzsch S; Okitsu SL; Svenungsson E; Gunnarsson I
  • Article: JOURNAL OF AUTOIMMUNITY. 2023;134:102951
    Preger C; Notarnicola A; Hellstrom C; Wigren E; Fernandes-Cerqueira C; Kvarnstrom M; Wahren-Herlenius M; Idborg H; Lundberg IE; Persson H; Graslund S; Jakobsson P-J
  • Show more

All other publications

Grants

  • Swedish Research Council
    1 January 2024 - 31 December 2026
    Prostaglandin (PG) E2 is formed from arachidonic acid by the enzymatic actions of either cyclooxygenase (COX)-1 or COX-2 into PGH2, which is further metabolized by microsomal prostaglandin E synthase-1 (mPGES-1) into PGE2. mPGES-1 has emerged as a cardiovascular safe anti-inflammatory drug target. Our characterizations of inhibitors of mPGES-1 demonstrate their potent anti-inflammatory actions while causing relaxation of arteries. mPGES-1 inhibition also significantly protects heart functions following myocardial infarction in vivo. The underlying mechanisms include inhibition of PGE2 biosynthesis, an increase of local prostacyclin formation, no effects on the ADMA-NO pathway and an unbroken formation of anti-inflammatory PGD2/15-deoxy-PGJ2 ( a cyclopentenone). These compounds are considered anti-inflammatory and antiviral and recognized as a part of the family “specialized pro-resolving lipid mediators”. We have identified MGST3 as the key enzyme conjugating cyclopentenone with glutathione. Inhibition of MGST3 leads to increased 15-deoxy-PGJ2 levels with lesser amounts of PGE2. We aim to characterize MGST3 as a novel modulator of inflammation. Furthermore, we will investigate prostaglandins and other lipids as biomarkers for rheumatoid arthritis. We will also characterize our findings demonstrating activation of the thromboxane A2 pathway and platelet activation as a likely mechanism of action for the severe cardiovascular side effects observed for JAK inhibitors.
  • Swedish Research Council
    1 January 2023 - 31 December 2025
    SLE is a heterogeneous autoimmune disease, characterized by the production of autoantibodies. Vascular disease (VD) is a major cause of early morbidity and mortality. Based on clinical experience and unsupervised clustering of 13 clinically relevant autoantibodies in 911 patients, we identified 4 SLE subgroups. Roughly outlined below:Anti-SSA/SSB, skin manifestations, Sjogren’s syndrom, HLA-DRB1*03Anti- dsDNA/nucleosome/Sm, nephritis, enhanced atherosclerosis, early onset, HLA-DRB1*15aPL, clotting disorders, HLA-DRB1*04No autoantibodies, late onset, no HLA association.Aim: To identify mechanisms contributing to autoimmunity and VD, by analyses of the 4 SLE subgroups separately.Method: We have since 1995 followed well-characterized cohorts, comprising &gt
    800 SLE, and 320 controls, every 10 years. Follow-up is ongoing at the clinic and in the National Patient Registries (NPR), where we also identify all Swedish SLE patients (N=7000) and 10 controls/patient.We seek to determine if the 4 groups differ regarding:Proteomics, new autoantibodies and microparticles (vesicles of cellular origin).Blood samples drawn during the different menstrual phases in women with SLE (new approach).Vascular function in the heart, as determined by cardiac magnetic resonance investigation.VD and long-term outcomes in NPRSignificance: Our results can impact how we diagnose and treat SLE in the future. VD mainly affects groups 2 and 3 but by different mechanisms, calling for tailored preventive treatment.
  • Swedish Heart-Lung Foundation
    1 January 2021 - 31 December 2023

News from KI

Events from KI